Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | IL18 | Q14116 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 7/20 | 0.43 |
| ▸ | MAOB | P27338 | 7/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6557043 | 0.93 | MAOA (0.51) | CYP19A1PARP15PARP10PARP2SRC | |
| SCHEMBL6153715 | 0.89 | SRC (0.46) | SRCRAB9AMEN1LMNAMAPT | |
| SCHEMBL6856729 | 0.86 | SRC (0.56) | SRCRAB9AMEN1LMNAMAPT | |
| SCHEMBL3163442 | 0.84 | PGR (0.47) | CYP19A1PARP10LMNAKDM4EALDH1A1 | |
| SCHEMBL6853633 | 0.83 | SRC (0.53) | PARP10SRCRAB9AMEN1LMNA | |
| SCHEMBL11222905 | 0.83 | MAOB (0.59) | SRCRAB9AMEN1LMNAMAPT | |
| SCHEMBL505351 | 0.83 | PARP10 (0.53) | CYP19A1PARP15PARP10PARP2RAB9A | |
| SCHEMBL31599170 | 0.83 | SRC (0.53) | PARP10SRCRAB9AMEN1LMNA | |
| SCHEMBL30185052 | 0.83 | CYP19A1 (0.54) | CYP19A1SRCRAB9AMEN1LMNA | |
| SCHEMBL28686276 | 0.83 | CYP19A1 (0.54) | CYP19A1SRCRAB9AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172560-A1 | PROCESS FOR PREPARATION OF CRISABOROLE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2020-06-04 | — | — | US | disclosed |
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1882684-A1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-01-30 | — | — | EP | disclosed |
| EP-1392643-B1 | TRISUBSTITUTED-N- (1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | ABBOTT LAB (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6831193-B2 | Treating pain, urinary incontinence and bladder overactivity; P2X receptors are cation-permeable ion channels | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | ABBVIE INC. | 2003-05-01 | — | — | US | disclosed |
| US-20020173665-A1 | Trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit P2X3 and P2X2/3 containing receptors | ABBOTT LABORATORIES | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173665-A1 | Trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit P2X3 and P2X2/3 containing receptors | P2RX3, P2RX1, P2RX2 | CYP19A1 1751/4885PARP15 2236/4885PARP10 2057/4885 |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | CYP19A1 1203/4885PARP15 2102/4885PARP10 1877/4885 |
| US-20200172560-A1 | PROCESS FOR PREPARATION OF CRISABOROLE | CFB, F13B, C9 | CYP19A1 306/4885PARP15 1819/4885PARP10 3652/4885 |
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | P2RX3, P2RX1, P2RX2 | CYP19A1 1345/4885PARP15 2414/4885PARP10 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.